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DEndovascular stent graft placement in patients with type B aortic
dissection: A meta-analysis in China
Jiang Xiong, PhD, MD,a Bo Jiang, PhD,b Wei Guo, MD,a Shen-Ming Wang, PhD, MD, FACS,c and
Xin-Yuan Tong, BMd
Objective:We summarized all published studies for endovascular stent graft placement among patients with type
B aortic dissection in China with respect to clinical success, complications, and outcomes.
Methods: A meta-analysis was performed on all published studies of retrograde endovascular stent graft place-
ment encompassing 3 or more patients with type B aortic dissection. Thirty-nine studies, involving a total of 1304
patients from January 2001 to December 2007, were included.
Results: The average patient age was 52 years. Procedural success was reported in 99.2%  0.1% of patients.
Major complications were reported in 3.4%  0.1% patients, with the most severe neurologic complications in
0.6%. Periprocedural stroke was encountered more frequently than paraplegia (0.2% vs 0%). The overall 30-day
mortality was 2.6% 0.1%. In addition, 1.5% 0.1% of patients died over a mean follow-up period of 27.1
17.5 months. Life-table analysis yielded overall survival rates of 96.9% at 30 days, 96.7% at 6 months, 96.4% at
1 year, 95.6% at 2 years, and 95.2% at 5 years.
Conclusion: Although therapy with traditional medicines still remains the first line of treatment for type B aortic
dissection, endovascular stent graft placement has shown its advantages, with a success rate of 99% or greater in
a select cohort. The technical survival rate, major complications, and acute and midterm survival rates in the Chi-
nese-language literature appeared to favorably compare with that seen in published literature. This analysis is the
first to provide an overview of the currently available literature on endovascular stent graft placement in type B
aortic dissection in China.Supplemental material is available online.
A growing body of evidence has demonstrated the efficacy of
endovascular repair for aortic dissection (AD). However,
long-term studies on whether endovascular stent graft place-
ment is the optimal initial treatment for elective cases of type
BAD remain inconclusive.1 Eggebrecht and colleagues2 and
Resch and associates,3 respectively, reported multicenter ret-
rospective studies of endovascular stent graft placement in
patients with type B AD. However, the data were extracted
exclusively from the English-language medical literature
and mostly represented Western countries, such as those in
Europe andNorth America. In 1998, endovascular stent graft
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for patients with type B AD in China, and since then, more
than 1300 patients with type B AD have opted for the treat-
ment. To date, nearly all single-center studies of endovascu-
lar stent graft placement in patients with type B AD were
published in the Chinese-language literature, with no multi-
center analysis in China being reported.
The aim of this meta-analysis was to summarize all avail-
able published data with respect to clinical success, compli-
cations, and outcomes of endovascular stent graft placement
among Chinese patients with type B AD. This Chinese
multicenter report of endovascular stent graft placement in
patients with type B AD will provide a direct comparison
with existing studies. Most importantly, this study will
provide an insight into the pattern of regional practice and
patient distribution and demographic uniqueness.
MATERIALS AND METHODS
Data Sources and Study Selection
‘‘Aorta,’’ ‘‘dissection,’’ and ‘‘stent’’ were used as the key words for
a comprehensive search of both the English- and Chinese-language litera-
ture in the PubMed, MEDLINE, CBMdisc (Chinese Biomedical Database),
and CNKI (Chinese National Knowledge Infrastructure) databases. All Chi-
nese studies on endovascular stent graft treatment published between Janu-
ary 2001 and December 2007 were identified for further analysis. Several
criteria were applied to determine whether articles would qualify for the
analysis: (1) articles including patients with type B AD undergoing retro-
grade endovascular stent graft placement into the descending thoracic aorta
were selected for data extraction; (2) articles reporting on antegrade, surgi-
cal (‘‘open’’) stent graft placement through the aortic arch were notardiovascular Surgery c Volume 138, Number 4 865
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DAbbreviation and Acronym
AD ¼ aortic dissection
included; (3) a minimum series of 3 patients with type B AD treated with
stent grafts was required for inclusion; and (4) case reports were not
included. The selected articles were carefully reviewed, and data were
extracted.
Data Extraction and Statistical Analysis
Each article was analyzed by using a standardized protocol according to
the 53 predefined variables regarding clinical characteristics, procedural
data, and in-hospital and long-term outcomes (see Table E1). Articles con-
taining insufficient data (<25% of predefined variables) were excluded
from the data extraction. Only articles including patients with type B AD
subjected to endovascular stent graft placement were included, and articles
with patients with other thoracic aortic pathologies (eg, thoracic aortic aneu-
rysms) were discarded. Unspecified information was classified as not avail-
able. As a result, the number of patients (denominator) varies, with the
specific variables reported in the analysis.
Rates of events were calculated as the number of events divided by the
number of treated patients with available data. The approach to calculating in-
dividual rates for different studies and to combining these rates into aweighted
average produces identical results if the weights are defined as the proportion
of available patients provided in a specific study.Results are presented asmean
 standard error or median and range, where appropriate. No adjustment for
multiple testing was applied because the statistical analysis was performed
in an exploratory manner. Comparisons between patients in relation to publi-
cation date or in relation to operator’s experience were made by using the 2-
sided Student’s t test for continuous variables. The life-table nonparametric
method was used to generate estimates of survival at 30 days, 6 months, 1
year, 2 years, and 5 years. The Kaplan–Meier nonparametric method was
used to generate estimates of 30-day mortality and 1-year survival in relation
to publication date or in relation to operator’s experience, and these values
were compared by using the log-rank test. The 30-day procedure-relatedmor-
tality of patients undergoing stent graft placement was compared with that of
non–procedure-related mortality by using the log-rank test.
Definitions
AD was classified according to the Stanford classification. Dissection
was considered an acute event if it occurred within the first 14 days from
onset of symptoms, whereas it was considered chronic when occurring be-
yond 14 days. Complications were classified as major when life-threatening
or prompting major therapeutic consequences (eg, access complications re-
quiring surgical revision), whereas complications that did not require further
treatment (eg, transient renal failure not requiring dialysis) were defined as
minor. For the stent indication, Chinese vascular centers initially followed
the indications for stent placement for type B dissection described by Nie-
naber and coworkers.4 However, with accumulating experience, some expe-
rienced centers extended indications 1, 3, and 7.4 Specifically, (1) when the
distance from the entry site to the left subclavian artery is shorter than 1.5
cm, endovascular repair was still made after a left carotid–subclavian artery
bypass5-7; (2) endovascular repair was also performed, even when the max-
imal aortic diameter was less than 5.5 cm5-7; and (3) when the bilateral iliac
arteries were tortuous and stenosed, endovascular repair could be performed
through the abdominal aorta.5-7 The technical details of endovascular re-
pairs were described by Nienaber and colleagues.8 Procedural success
was defined by the technically successful deployment of the endoprosthesis
at the intended target location. Any death that occurred suddenly or could
not be related to other causes was classified as being caused by aortic rup-
ture. Reintervention was defined as the need for any surgical conversion or
additional endovascular stent graft procedures. Procedure-related complica-866 The Journal of Thoracic and Cardiovascular Surtions refer to complications that are related to endovascular stent placement
(eg, retrograde dissection, organ or peripheral artery malperfusion, dissec-
tion rupture, type I endoleak, and stroke for subclavian artery occlusion).
Non–procedure-related complications indicate complications that are not re-
lated to endovascular stent placement (eg, myocardial infarction, cancer,
and multiple organ failure or stroke with no relation to stent graft treatment).
Studies were analyzed according to the reported total number of patients
treated with endovascular stent graft placement, including dissections and
other diseases of the thoracic aorta (eg, thoracic aortic aneurysms), to eval-
uate the potential influence of the operator’s experience on outcomes. Cen-
ters with a published total number of patients beyond the median (>16
patients) were considered more experienced than those with total numbers
below the median. In addition, the results of stent graft placement were an-
alyzed in relation to the study publication date. Specifically, studies pub-
lished between 2001 and 2004 represent the earlier experience, and those
published between 2005 and 2007 are considered the latest experience.
RESULTS
Study Selection
A total of 70 Chinese-language publications published be-
tween January 2001 and December 2007 met the inclusion
criteria. Twenty-three of these articles were excluded be-
cause of potential duplicate publications, and 7 publications
were excluded for insufficient data. One study that incorpo-
rated complementary data from another study was also
excluded for data extraction. Thirty-nine studies were even-
tually selected for data extraction and analysis. A total of
1359 patients who underwent endovascular stent graft repair
of the thoracic aorta were included in this analysis. Of these
patients, 1304 (96.0%) had B-type AD (Table 1).5-7,9-45
Patient Characteristics
Seven hundred thirty-eight of 922 patients with available
data had hypertension, and 130 of 696 patients with available
data had cardiovascular risk factors, including 91 with coro-
nary heart disease, 2 with aortic incompetence, and 37 with
cardiac insufficiency (Table 2). Of note, 23 of 1139 patients
had evidence of aortic rupture, as shown with computed to-
mographic angiography, magnetic resonance angiography,
or digital subtraction angiography. For the grafts used in
these studies, 726 grafts from 656 available cases were indi-
cated, including Talent (Medtronic, Inc, Minneapolis, Minn;
n¼ 341), Aegis (Microport, Inc, Shanghai, China; n¼ 189),
Vasoflow (Weike Medical Apparatus and Instrument, Inc,
Suzhou, China; n ¼ 18), Endofit (Endomed, Inc, Phoenix,
Ariz; n ¼ 15), Zenith (Cook, Inc, Bloomington, Ind; n ¼
6), Powerlink (Endologix, Inc, Irvine, Calif; n ¼ 2), Aortec
(YTH Biological Material Scitech, Inc, Beijing, China; n ¼
55), Griking (Grikin Advanced Materials, Inc, Beijing,
China; n ¼ 36), Ankura (Lifetech Scientific, Inc, Shenzhen,
China; n ¼ 15), and homemade grafts (n ¼ 49).
Procedural Data and In-Hospital Course
The stent graft placement procedure was successful in
99.2%  0.1% of patients (Table 3). Emergency surgical
conversion was required in 0.7% 0.1% of patients (Tablegery c October 2009
TABLE 1. Detailed overview over the analysis reports
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Late surgical
conversion
(n)
Aortic rupture
during follow-up
(n)
Late mortality
during follow-up
(n)
0 0 0
1 0 2
0 0 0
NA NA NA
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Patients with
type B AD
(n)
Pro
success
(n)
Emergency
conversion
(n)
Overall
complications
(n)
Major
complications
(n)
Overall neurologic
complications
(n)
Paraplegia
(n)
30-d
Mortalit
(n)
Shi5 2005 150 150/150 0 3 3 1 0 2
Guo6 2005 159 159/159 0 6 6 1 0 6
Li9 2001 5 3/4 1 3 3 0 0 1
Li10 2002 20 19/20 1 2 2 0 0 1
Huang11 2002 6 6/6 0 0 0 0 0 0
Wang12 2003 18 16/18 2 6 2 0 0 1
Zhang13 2003 10 8/10 0 1 1 0 0 1
Zhang14 2003 6 6/6 0 0 0 0 0 0
Shu15 2004 19 19/19 0 0 0 0 0 0
Li16 2004 11 11/11 0 0 0 0 0 0
Wu17 2004 15 15/15 0 0 0 0 0 0
Wang18 2004 5 5/5 0 1 1 0 0 0
Yang19 2005 16 16/16 0 1 0 0 0 0
Jiang20 2005 10 10/10 0 1 1 0 0 1
Su21 2005 22 22/22 0 1 1 0 0 1
Lin22 2005 26 26/26 0 0 0 0 0 0
Shan23 2005 22 22/22 0 1 1 0 0 1
Bao24 2005 7 7/7 0 0 0 0 0 0
Yu25 2006 12 12/12 0 0 0 0 0 0
Yu26 2006 180 179/180 1 2 2 0 0 2
Xu27 2006 76 76/76 0 7 6 2 0 4
Wang28 2006 12 12/12 0 0 0 0 0 0
Luo29 2006 22 21/22 1 1 1 0 0 0
Li30 2006 17 17/17 0 NA NA NA NA 0
Adeliai31 2006 23 22/22 0 2 1 1 0 1
Zhang32 2006 4 4/4 0 0 0 0 0 0
Wang33 2006 8 8/8 0 0 0 0 0 0
Luo34 2006 55 55/55 0 1 1 0 0 1
Zhao35 2006 15 15/15 0 0 0 0 0 0
Wang36 2006 34 34/34 0 2 2 0 0 2
Tan37 2006 15 15/15 0 3 3 0 0 3
Yu38 2006 8 8/8 0 0 0 0 0 0
Li39 2006 42 42/42 0 0 0 0 0 0
Mei,40 Jing7 2007,
2003
146 143/145 2 7 6 1 0 6
Liu41 2007 38 37/38 1 1 1 0 0 0
Cao42 2007 5 5/5 0 0 0 0 0 0
Hu43 2007 9 9/9 0 1 0 0 0 0
Dong44 2007 10 10/10 0 0 0 0 0 0
Jing45 2007 46 46/46 0 4 0 2 0 0
All 1304 1290/1301 (99.2%) 9/1304 (0.7%) 57/1284 (4.4%) 44/1284 (3.4%) 8/1284 (0.6%) 0/1284 (0%) 34/1304 (2.
AD, Aortic dissection; NA, not applicable.
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D3), accounting for the total in-hospital conversion rate. In-
hospital complications were reported in 4.4%  0.2% of
patients (Table 3). Complications were predominantly of
major clinical significance (3.4%  0.1%), whereas minor
complications were reported less frequently (1.0% 
0.1%). The most critical in-hospital complications were re-
lated to retrograde extension of the dissection into the ascend-
ing aorta (0.4%  0.0%) and neurologic complications
(0.6% 0.0%). Concerning neurologic complications, peri-
procedural stroke occurred in 0.2%  0.0% of patients,
whereas no paraplegia was reported in 1284 patients.
Thirty-four of 1304 patients with available data died during
the in-hospital period (Table 3), yielding an overall in-hospi-
tal mortality rate of 2.6% 0.1%.Within the 30-day period,
therewere no additional deaths, yielding a 30-day (operative)
mortality rate of 2.6%  0.1%.
Follow-up Data
Patients were examined 1, 3, 6, 12, 24, and 60 months af-
ter discharge with computed tomographic scanning. The ma-
jor parameters for the follow-up period have included false
luminal thrombosis, morphous of stent, type I endoleak,
and organ or peripheral arterial blood supply. Follow-up in-
formation was available for all 1304 patients (Table 4). The
time to follow-up (27.1  17.5 months) was available for
only 1151 patients. False lumen thrombosis was reported
in 92.9%  0.5% of the patients (Table 4). Late surgical
conversion was performed in 0.8%  0.1% of the patients,
and adjunctive endovascular stent graft procedures were per-
formed in 1.6%  0.1% of the patients. Therefore the total
reintervention rate was 2.4%  0.1% over the follow-up
period of 27.1  17.5 months.
Aortic rupture occurred in 0.5%  0.0% of the patients
during the follow-up period. A total of 1.5%  0.1% of
the patients died during the follow-up period. Figure E1
shows survival rates for all patients in whom the exact time
to death was available in life-table format. Specifically, the
survival rates were 96.9% at 30 days, 96.7% at 6 months,
96.4% at 1 year, 95.6% at 2 years, and 95.2% at 5 years.
TABLE 2. Patient characteristics
Data
available (n)
No. of events
or cases
Total no. of studies included 39 
Total no. of patients reported 1359 
No. of patients with type B AD 1304 96%
No. of patients with type B AD
per study
39 16 (4–180)*
Patient age (y) 1296 52.1
Male sex 1277 1118 (86.8%  0.2%)
Acute dissection 744 273 (36.7%  1.0%)
Presenting with rupture 1139 23 (2.0%  0.2%)
AD, Aortic dissection. *Median.868 The Journal of Thoracic and Cardiovascular SurResults of Stent Graft Placement in Relation to
Publication Date
Reported technical success rates were lower in the early
studies published between 2001 and 2004 (94.7% 
0.7%) when compared with the more recent studies pub-
lished between 2005 and 2007 (99.6%  0.0%, P< .001,
Table 5). The overall rate of complications was consistently
higher in the earlier studies (11.4%  1.6% vs 3.8% 
0.1%, P<.001). However, the rate of neurologic complica-
tions, in particular, was lower in comparison with that seen
in the more recent studies (0% vs 0.7 0.0%, P<.001). No
significant difference was identified in operative or 1-year
mortality between the 2 groups (Table 5).
Influence of Operator’s Experience
As shown in Table 6, centers with a total number of pa-
tients beyond the median had a better procedural success
TABLE 4. Follow-up data over 27.1 ± 17.5 months after stent graft
placement
Data
available (n) No. of events (n)
Duration of follow-up (mo) 1151 27.1  17.5
False lumen thrombosis 1037 963 (92.9%  0.5%)
Late surgical conversion 1045 8 (0.8%  0.1%)
Adjunctive endovascular
procedures
1062 17 (1.6%  0.1%)
Late complications 1062 38 (3.6%  0.1%)
Late mortality 1033 15 (1.5%  0.1%)
TABLE 3. In-hospital data
Data
available (n) No. of events
Procedure success 1301 1290 (99.2%  0.1%)
No. of stent grafts per patient 656 1.1
Surgical conversion 1304 9 (0.7%  0.1%)
Adjunctive endovascular
procedures
1304 16 (1.2%  0.2%)
Overall complications 1284 57 (4.4%  0.2%)
Major complications 1284 44 (3.4%  0.1%)
Minor complications 1284 13 (1.0%  0.1%)
Procedure-related complications 1301 25 (1.9%  0.1%)
Retrograde type A AD 1301 5 (0.4%  0.0%)
Access complications 1301 5 (0.4%  0.0%)
Neurologic complications 1284 8 (0.6%  0.0%)
Stroke 1284 3 (0.2%  0.0%)
Paraplegia 1284 0%
In-hospital mortality 1304 34 (2.6%  0.1%)
In-hospital mortality, procedure
related
1304 10 (0.8%  0.0%)
In-hospital mortality, non–procedure
related
1304 21 (1.6%  0.1%)
30-d mortality 1304 34 (2.6%  0.1%)
AD, Aortic dissection.gery c October 2009
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Data available (n)
P valuePublication date, 2001–2004 (n ¼ 114) Publication date, 2005–2007 (n ¼ 1187)
No. of publications 10 29 
Patients/center (median) 10.5 (5–20) 22 (4–180) 
Procedural success 114 94.7%  0.7% 1187 99.6%  0.0% <.001
Overall complications 114 11.4%  1.6% 1170 3.8%  0.1% <.001
Neurologic complications 114 0% 1170 0.7%  0.0% <.001
30-d Mortality 114 3.5%  0.5% 1187 2.5%  0.1% .516*
1-y Survival 63 96.8%  0.9% 970 96.3%  0.1% .895*
*Log-rank test.A
C
Drate and lower rates of complications and mortality than cen-
ters with low numbers of treated patients (98.4% 0.4% vs
99.3% 0.1% in procedural success rate,P<.001; 5.9%
0.9% vs 4.2%  0.1% in overall complications, P ¼ .01;
and 3.2%  0.5% vs 2.5%  0.1% in 30-day mortality
rate, P< .001). However, the rate of neurologic compli-
cations was higher in the centers with a total number of pa-
tients beyond the median (0.7%  0.0% vs 0%, P< .001,
Table 6).
Procedure-Related Versus Non–Procedure-Related
Mortalities
Figure E2 depicts the procedure-related and non–proce-
dure-related mortalities over the 30-day treatment period
after the patients were accepted. Non–procedure-related
mortality was higher than procedure-related mortality
(1.8%  0.1% vs 0.8%  0.0%, P ¼ .016).
DISCUSSION
In this retrospective study we evaluated, by means of
a large-scale meta-analysis, the efficacy of endovascular stent
graft treatment for type B AD in China. Although the tradi-
tional antihypertensive therapy remains the first-line treatment
for type B AD, endovascular stent graft placement is gaining
more and more attention, especially with the high technical
success rate and improved morbidity and mortality compared
with those seen with its surgical counterpart.8,46 The concept
of endovascular stent graft placement was propelled by the de-
sire to induce aortic remodeling by means of exclusion of the
false lumen and thrombosis of the false lumen and, at the sameThe Journal of Thoracic and Ctime, avoiding the risks associatedwith open surgical interven-
tion. Clinical studies have suggested that patients with type B
ADundergoing endovascular stent graft placement have a bet-
ter midterm prognosis than those receiving antihypertensive
medicine or undergoing traditional open surgical interven-
tion.47 For instance, Nienaber and colleagues4 showed that
in comparison with the traditional surgical treatment, stent
grafting had a lower perioperative mortality (0% vs 8% for
surgical treatment), lower mortality after 30 days (0% vs
8%), and lowermortality after 1 year (0% vs 33%) in patients
with subacute or chronic type B AD. Similarly, the Investiga-
tion of Stent Grafts in Patients with Type B Aortic Dissection
trial in Europe showed that treatment of uncomplicatedADby
means of stent grafting plus antihypertensive medications has
a 1-year survival rate of 95% in contrast to 77% for patients
receiving antihypertensive treatment alone.8 In addition, the
European Collaborators on Stent Graft Techniques for
Thoracic Aortic Aneurysm and Dissection (EUROSTAR)
study showed that for 131 patients with AD (57% with com-
plicated AD and 43% with uncomplicated AD) treated by
means of endovascular stent grafting, the primary technical
success was 89%, and paraplegia occurred in just 0.8% of
patients. The outcome at 1 year was more favorable for stent
treatment with regard to aortic expansion (0%) and late
survival (90%).48
Our study analyzed 1304 patients with type B dissection
who underwent endovascular stent graft placement between
2001 and 2007 in China and demonstrated that endovascular
stent graft treatment of AD was performed with a technical
success rate of greater than 99%. Furthermore, our dataTABLE 6. Influence of endovascular experience
Data available (n)
Endovascular experience, 16 patients (n ¼ 188) Endovascular experience,>16 patients (n ¼ 1113) P value
No. of publications 20 19 
Patients/center (median) 9.5 (4–16) 34 (17–180) 
Procedural success 188 98.4%  0.4% 1113 99.3%  0.1% <.001
Overall complications 188 5.9%  0.9% 1096 4.2%  0.1% .01
Neurologic complications 188 0% 1096 0.7%  0.0% <.001
30-d Mortality 188 3.2%  0.5% 1113 2.5%  0.1% <.001*
1-y Survival 130 93.9%  0.8% 903 96.7%  0.1% .198*
*Log-rank test.ardiovascular Surgery c Volume 138, Number 4 869
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placement, which is comparable with the reported survival
rates aftermedical or surgical treatment of typeBAD. For ex-
ample, Dake and associates49 showed that stent grafting was
associated with a 16% mortality within 30 days in patients
with acute-type AD who had life-threatening complications.
This figure for the same category of patients treated conven-
tionally with an emergency surgical procedure is approxi-
mately 40% and as high as 70% for patients treated with
drugs.49-51 In addition, Hagan and colleagues52 showed
31.4% and 10.7% of in-hospital mortalities for acute type
B AD managed surgically and medically, respectively. Al-
though our study and others support the idea that stent graft-
ing is the optimal treatment for elective cases of type BAD in
terms of acute and midterm survival rates, one should be ex-
tremely careful in drawing any conclusions without a ran-
domized direct comparison with drug or surgical treatment
strategies because patient selection might differ. Neverthe-
less, drug therapy is still the first-line treatment for type B
AD, and stent grafting might have the potential to replace
or supplement drug therapy.
In comparison with the study by Eggebrecht and col-
leagues,2 our study of the Chinese-language literature
suggests favorable rates of technical success, major compli-
cations, and improved acute and midterm survival. This
might be because, first of all, the average age for patients
with type B AD in our study is 10 years younger than that
in the patients in the study by Eggebrecht and colleagues.
In addition, some risk factors are much lower in our study
than those in the study by Eggebrecht and colleagues. For
example, the rate of acute dissection is 36.7%  1.0% in
our study compared with 58.1% 1.8% in the study by Eg-
gebrecht and colleagues. The rate of rupture dissection is
2.0%  0.2% in our study compared with 16.1%  1.2%
in the study by Eggebrecht and colleagues. These risk factors
have an effect on the patient’s ability to tolerate the treatment
and consequently have an effect on the outcome.
Second, the technique of stent grafting was applied in
China 2 years after it was introduced to Europe and North
America. This allowed the Chinese surgeons to have more
time and chance to learn from their foreign counterparts,
gaining both technical experience and the experience to as-
sess the indications of the patients.
Third, our data reveal that this technique was being used
in 4 major vascular surgery centers in China (Table 1), with
more than 145 cases in each center. The patients from these 4
centers account for 48.6% of all cases (634/1304), and the
technical success rate is 99.5% (631/634). Because these 4
vascular surgery centers5-7,26 have a wealth of experience
and that ensures that nearly half of the cases of type B dissec-
tion in our study have a high successful rate and a high early
and midterm survival rate. In contrast, in the study by Egge-
brecht and colleagues,2 only a single center has an experi-
ence of more than 100 cases (20.9% [127/609]), and the870 The Journal of Thoracic and Cardiovascular Surother 79.1% of cases (582/609) were scattered over 38 vas-
cular surgery centers, with the number of cases ranging from
3 to 38. Therefore we believe these contribute to the better
success rate and the better rates of early and midterm sur-
vival in our study.
Neurologic complications, especially paraplegia, remain
the most severe potential complications of stent graft place-
ment, as for surgical repair of type B dissection. Occlusion
of numerous critical intercostal arteries (Adamkiewicz ar-
tery) with stent grafts is widely believed to be responsible
for the increased risk of paraplegia.53 In particular, simulta-
neous abdominal and thoracic aortic repair with loss of lum-
bar and intercostal arteries appears to pose an increased risk
of spinal cord damage because of insufficient collateral cir-
culation.54 Our analysis has shown that the overall risk of
neurologic complications in patients treated with stent graft-
ing was 0.6%, with none having paraplegia. In addition, our
data demonstrated that stroke occurred in 0.2% of patients
after stent graft treatment, which, again, is significantly
lower than reported in the study by Eggebrecht and col-
leagues.2 We believe that this is related to the age of the pa-
tients (52.1 years in our study vs 61.0 years in the report by
Eggebrecht and colleagues) because younger patients might
have a lower incidence of atherosclerosis and a relatively
better circulation in the medium and small arteries. When
the traffic artery or the left subclavian artery is occluded
by stent grafting, other arteries can compensate for the blood
supply for the spinal cord or brain, thereby reducing the in-
cidence of paraplegia and stroke.
Although a favorable survival rate and a lower incidence
of neurologic complications appear to be somewhat encour-
aging in these initial experiences, it should be noted that in-
hospital complications were encountered in 4.4% of patients
and 40% of these complications were related directly to the
procedure itself. Figure E2 shows a statistically significant
difference between the mortality rate caused by a procedure-
related process and that caused by a non–procedure-related
process during the 30-day postoperative period. However,
it is interesting that we found this difference to be time re-
lated. As shown in Figure E2, this difference was not appar-
ent within 5 days after the procedure. The tendency of
procedure-related mortality curve suggests that procedure-
related mortality most frequently occurs within 5 days of
the operation, whereas the difference appeared 5 to 30
days after the operation. This could be useful information
for the implication analysis after surgical intervention.
Our analysis suggests that centers with an experience of
more than 16 stent graft procedures had a significantly
higher success rate and a lower rate of complications than
less experienced centers. Our data also suggested that the
technical success rates have improved over time, which is
accompanied by a decrease in 30-day mortality. However,
neurologic complications have increased in the more recent
studies compared with the earlier studies. This could begery c October 2009
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ment have been expanded to include some high-risk patients
who are more prone to complications while the experience in
endovascular stent graft treatment grows. This was also evi-
denced by the fact that the spectrum of acute and midterm
complications has broadened to include potentially disas-
trous events other than paraplegia or stroke.55
Our meta-analysis highlights some other technical limita-
tions of endovascular stent graft placement in patients with
type B AD. Stent grafting failed to abolish the false lumen
in 7% of patients, suggesting that it might not be a definitive
treatment for type B AD. Even in the presence of a throm-
bosed thoracic false lumen, the distal thoracic or abdominal
aorta might enlarge during follow-up. Therefore there is
a continued risk for aortic rupture (about 0.5% during fol-
low-up) after stent graft placement and a need for adjunc-
tive stent graft placement or a need for open operations in
4% of patients over time. However, the incidence of aortic
rupture and the need for repeat endovascular or surgical in-
tervention might also be related to the progression of the
disease itself and might not necessarily reflect treatment
failure. This is supported by the fact that 11% to 20%
and 10% to 44% of patients with type B AD require re-
peated operations when treated with drugs or treated surgi-
cally, respectively.56,57
Our analysis is the first to provide an overview of the lit-
erature on endovascular stent graft placement in patients
with type B AD in China. Although it is not a prospective
and randomized comparison with other treatment strategies
for patients with type B AD, it provides an important insight
into technical success, potential advantages and complica-
tions, and survival rates. However, several unavoidable lim-
itations exist in this study.
First, the retrospective nature of this study might lead to
potential bias in data collection, which would handicap the
clinical applicability of the findings. Second, in general, it
is impractical to include all hospitals in all regions in China.
Although we were trying to be inclusive and systematic in
our approach, we could only study patients who were admit-
ted to these tertiary care centers. Third, there might be refer-
ral bias based on the type B AD of these medical centers.
Finally, there might be some cases of type B AD that might
have been overlooked. Nevertheless, we believe that our
data truly represented valuable and reliable information re-
lated to stent placement for type B AD in China.
We thank Dr Rowan Flynn for the English-language editing and
proofreading.
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DFIGURE E1. The overall survival curve of patients undergoing stent graft
placement. The survival rate was generated by using the life-table nonpara-
metric method. The available number of patients was 1033 at 1 month, 719
at 20 months, 400 at 40 months, and 155 at 60 months. Specifically, the sur-
vival rates were 96.9% at 30 days, 96.7% at 6 months, 96.4% at 1 year,
95.6% at 2 years, and 95.2% at 5 years.The Journal of Thoracic and CarFIGUREE2. Thirty-daymortality of patients undergoing stent graft place-
ment with procedure-related processes in comparison with those with non–
procedure related processes. The mortality data were generated by using the
Kaplan–Meier method. Non–procedure-related mortality (triangles) was
higher than procedure-related mortality (squares; 1.8%  0.1% vs 0.8%
 0.0%, P ¼ .016) by using the log-rank test.TABLE E1. Clinical characteristics, procedural data, and in-hospital and long-term outcomes of patients undergoing stent graft displacement
List of variables abstracted from each article (if available)
Patient characteristics Procedural data
No. of patients with dissection Use of general anesthesia
Total no. of patients reported No. of stent grafts per patient
Age Stent graft diameter
Sex Stent graft length
Type of dissection Procedure success
Acuity of dissection Need for emergency surgical conversion
Presence of (contained) aortic rupture Procedure time
Cardiovascular risk factors Fluoroscopic time
Medical comorbidities Amount of contrast media
In-hospital data Follow-up data
Overall complications Duration of follow-up
Major complications Need for late surgical conversion
Minor complications Adjunctive endovascular procedureduring follow-up
Procedure-related complications Late complications
Retrograde type A dissection Late neurologic complications
Access complications Late retrograde type A dissection
Myocardial complications Aortic rupture during follow-up
Renal complications False lumen thrombosis
Visceral complications Stent migration
Pulmonary complications Shrinkage of false lumen diameter
Overall neurologic complications Increase of true lumen diameter
Paraplegia 30-d mortality
Stroke Overall late mortality during follow-up
Need for early surgical conversion Aorta-related late mortality
Adjunctive endovascular procedure Non–aorta-related late mortality
Length of intensive care unit stay
Length of hospital stay
Overall in-hospital mortality
Aorta-related mortality
Non–aorta-related mortalitydiovascular Surgery c Volume 138, Number 4 872.e1
